Quick Answer
Instil Bio, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
Instil Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0.00 -100.0% |
$138.0K |
| Revenue (ASC 606) | — | — | — | — | $0.00 -100.0% |
$138.0K |
| Net Income | -$71.37M +3.7% |
-$74.14M +52.5% |
-$156.09M +30.1% |
-$223.18M -42.3% |
-$156.79M -315.5% |
-$37.74M |
| Diluted EPS | -$10.70 +6.1% |
-$11.39 +52.5% |
-$24.00 +30.4% |
-$34.46 -2228.4% |
-$1.48 +37.3% |
-$2.36 |
| Total Assets | $203.52M -22.8% |
$263.57M -19.1% |
$325.63M -32.5% |
$482.13M -21.0% |
$609.98M +91.2% |
$319.01M |
| Cash and Equivalents | $6.64M -24.6% |
$8.80M -4.2% |
$9.20M -79.0% |
$43.72M +16.3% |
$37.59M -84.4% |
$241.71M |
| Stockholders Equity | $113.87M -32.8% |
$169.44M -25.0% |
$225.83M -37.9% |
$363.61M -34.5% |
$555.20M +1502.1% |
-$39.60M -474.6% |
| R&D Expense | — | — | $39.60M -71.9% |
$141.06M +31.5% |
$107.25M +452.9% |
$19.40M |
| Operating Income | -$78.58M -6.9% |
-$73.54M +53.8% |
-$159.17M +29.7% |
-$226.46M -45.6% |
-$155.56M -362.4% |
-$33.64M |
| Shares Outstanding | 6.78M +3.9% |
6.53M +0.3% |
6.50M +0.0% |
6.50M -95.0% |
129.03M +526.6% |
20.59M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2021 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2021 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$13.59M | +41.0% | +36.5% |
| Diluted EPS | September 30, 2025 | -$2.01 | +43.2% | +38.0% |
| Total Assets | September 30, 2025 | $211.77M | -22.3% | -8.3% |
| Cash and Equivalents | September 30, 2025 | $5.80M | -12.9% | -24.5% |
| Stockholders Equity | September 30, 2025 | $120.42M | -31.7% | -8.5% |
| R&D Expense | June 30, 2024 | $2.92M | -65.5% | -59.7% |
| Operating Income | September 30, 2025 | -$15.02M | +36.4% | +35.9% |
| Shares Outstanding | September 30, 2025 | 6.78M | +3.9% | +0.5% |
- Instil Bio, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
- Instil Bio, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Instil Bio, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2021.
- Instil Bio, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Instil Bio, Inc. reported Net Income of -$71.37 million for fiscal year 2025.
- Instil Bio, Inc. showed an increase of +3.7% in Net Income compared to the prior fiscal year.
- Instil Bio, Inc. reported Diluted EPS of $10.70 per share (loss) for fiscal year 2025.
- Instil Bio, Inc. showed an increase of +6.1% in Diluted EPS compared to the prior fiscal year.
- Instil Bio, Inc. reported Total Assets of $203.52 million for fiscal year 2025.
- Instil Bio, Inc. showed a decrease of -22.8% in Total Assets compared to the prior fiscal year.
- Instil Bio, Inc. reported Cash and Equivalents of $6.64 million for fiscal year 2025.
- Instil Bio, Inc. showed a decrease of -24.6% in Cash and Equivalents compared to the prior fiscal year.
- Instil Bio, Inc. reported Stockholders Equity of $113.87 million for fiscal year 2025.
- Instil Bio, Inc. showed a decrease of -32.8% in Stockholders Equity compared to the prior fiscal year.
- Instil Bio, Inc. reported R&D Expense of $39.60 million for fiscal year 2023.
- Instil Bio, Inc. showed a decrease of -71.9% in R&D Expense compared to the prior fiscal year.
- Instil Bio, Inc. reported Operating Income of -$78.58 million for fiscal year 2025.
- Instil Bio, Inc. showed a decrease of -6.9% in Operating Income compared to the prior fiscal year.
- Instil Bio, Inc. reported Shares Outstanding of 6.78 million shares for fiscal year 2025.
- Instil Bio, Inc. showed an increase of +3.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: